Toby Capstick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toby Capstick has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Ashleigh Goddard
Leeds Teaching Hospitals NHS Trust, Leeds (West Yorkshire), United Kingdom
2 shared publicationsGary Deakin
Leeds Teaching Hospitals NHS Trust, Leeds (West Yorkshire), United Kingdom
2 shared publications- Jennifer Kathleen Quint
Imperial College London
2 shared publications - Mark L. Levy
Locum General Practitioner, London, UK
2 shared publications - Anand Shah
Centre for Bacterial Resistance Biology, Department of Infectious Disease, Imperial College London, London, UK
1 shared publication - Andrew Bush
National Heart and Lung Institute, Imperial College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (10)
Real‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice
Timely management of exacerbations and optimisation of ongoing care are vital in preventing disease progression and preserving outcomes and quality of life in patients with bronchiectasis. This retrospective case review underscores the importance of the new ERS guidelines in supporting multidisciplinary teams to provide optimal care for their patients.
- 25 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (10)
Open AccessReal‐World Management of Difficult Exacerbations of Bronchiectasis: A Case Study to Illustrate How Guidelines Can Support Best Practice
Timely management of exacerbations and optimisation of ongoing care are vital in preventing disease progression and preserving outcomes and quality of life in patients with bronchiectasis. This retrospective case review underscores the importance of the new ERS guidelines in supporting multidisciplinary teams to provide optimal care for their patients.
- Open Access
- 17 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003601
Comparing paper Letters in addition to Emailed Audit and feedback in Refining Asthma treatment to Improve clinical and environmental Results in primary care through a cluster randomised controlled trial: the CLEAR AIR study
Background: Suboptimal use of preventer inhalers and salbutamol reliever overprescribing are associated with preventable asthma deaths and are a major source of primary care carbon emissions. Audit and feedback produces modest behaviour change by assessing clinical performance and delivering feedback to encourage improvement. Although feedback is increasingly delivered digitally, clinicians may respond more to additional printed feedback reports. We evaluated whether combined digital and paper feedback was more effective than digital-only feedback in promoting safer and greener asthma prescribing at the practice level. Methods: In this parallel, cluster randomised controlled trial, all 273 primary care practices in West Yorkshire were assigned within their primary care network clusters by stratified, permuted block randomisation to receive seven bimonthly reports on asthma prescribing either in ‘digital and paper’ (intervention) or ‘digital-only’ (control) formats. The primary outcome was the proportion of preventer inhalers prescribed in pressurised metred-dose devices due to their high carbon footprint. Intervention group allocation was concealed. The intention-to-treat population was analysed and adjusted for both potential confounders and preintervention achievement. Results: Final analysis assessed 270 practices in 26 clusters per arm due to practice mergers within the control group. There was no significant difference between the intervention groups based on change in the primary outcome (intervention—0.15%; control—0.19%; risk ratio—1.00; 95% CI 0.98 to 1.03) nor any secondary outcome. Analysis of both interventions combined showed a background trend of mixed improvement following feedback. Conclusions: There was no evidence that combined paper and digital feedback was more effective than digital-only feedback, despite the background of mixed improvements following both interventions. Challenges remain to understanding the barriers to influencing the prescribing of preventer inhalers and transitioning inhaler devices towards low-carbon ‘green’ alternatives; however, this study demonstrated the value of an efficient ‘real-world’ trial embedded within an existing quality improvement initiative. Trial registration number: NCT05761873 .
- 17 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003601
Open AccessComparing paper Letters in addition to Emailed Audit and feedback in Refining Asthma treatment to Improve clinical and environmental Results in primary care through a cluster randomised controlled trial: the CLEAR AIR study
Background: Suboptimal use of preventer inhalers and salbutamol reliever overprescribing are associated with preventable asthma deaths and are a major source of primary care carbon emissions. Audit and feedback produces modest behaviour change by assessing clinical performance and delivering feedback to encourage improvement. Although feedback is increasingly delivered digitally, clinicians may respond more to additional printed feedback reports. We evaluated whether combined digital and paper feedback was more effective than digital-only feedback in promoting safer and greener asthma prescribing at the practice level. Methods: In this parallel, cluster randomised controlled trial, all 273 primary care practices in West Yorkshire were assigned within their primary care network clusters by stratified, permuted block randomisation to receive seven bimonthly reports on asthma prescribing either in ‘digital and paper’ (intervention) or ‘digital-only’ (control) formats. The primary outcome was the proportion of preventer inhalers prescribed in pressurised metred-dose devices due to their high carbon footprint. Intervention group allocation was concealed. The intention-to-treat population was analysed and adjusted for both potential confounders and preintervention achievement. Results: Final analysis assessed 270 practices in 26 clusters per arm due to practice mergers within the control group. There was no significant difference between the intervention groups based on change in the primary outcome (intervention—0.15%; control—0.19%; risk ratio—1.00; 95% CI 0.98 to 1.03) nor any secondary outcome. Analysis of both interventions combined showed a background trend of mixed improvement following feedback. Conclusions: There was no evidence that combined paper and digital feedback was more effective than digital-only feedback, despite the background of mixed improvements following both interventions. Challenges remain to understanding the barriers to influencing the prescribing of preventer inhalers and transitioning inhaler devices towards low-carbon ‘green’ alternatives; however, this study demonstrated the value of an efficient ‘real-world’ trial embedded within an existing quality improvement initiative. Trial registration number: NCT05761873 .
- Open Access
- 2 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003861
Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application
Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the efficacy and safety of shorter, all-oral regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin), yet their implementation in the UK presents unique challenges, particularly around the antimicrobial stewardship (AMS) agenda, such as the lack of licensed drugs, pharmacokinetic/dynamic concerns, fragile supply chains and high cost of second-line antituberculosis drugs. This narrative review outlines how the UK has addressed implementation hurdles through coordinated efforts by the British Thoracic Society MDR-TB Clinical Advice Service and National Health Service England. This collaboration has facilitated the adoption of new regimens, with 54 out of 60 requests for using pretomanid-containing regimens approved in the UK up to January 2026. Furthermore, resources like the TB Drug Monographs and the shift to video-observed therapy have streamlined care delivery. The UK has effectively navigated the transition to shorter, all-oral MDR-TB regimens, significantly enhancing patient care and operational efficiency. The integration of clinical guidance, AMS principles, policy reform and specialised monitoring tools provides a robust framework for managing evolving treatment landscapes and delivering patient-centred care.
- 2 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003861
Open AccessImplementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application
Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated as MDR-resistant or rifampicin-resistant TB in 2024. Recent clinical trials have demonstrated the efficacy and safety of shorter, all-oral regimens such as BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin), yet their implementation in the UK presents unique challenges, particularly around the antimicrobial stewardship (AMS) agenda, such as the lack of licensed drugs, pharmacokinetic/dynamic concerns, fragile supply chains and high cost of second-line antituberculosis drugs. This narrative review outlines how the UK has addressed implementation hurdles through coordinated efforts by the British Thoracic Society MDR-TB Clinical Advice Service and National Health Service England. This collaboration has facilitated the adoption of new regimens, with 54 out of 60 requests for using pretomanid-containing regimens approved in the UK up to January 2026. Furthermore, resources like the TB Drug Monographs and the shift to video-observed therapy have streamlined care delivery. The UK has effectively navigated the transition to shorter, all-oral MDR-TB regimens, significantly enhancing patient care and operational efficiency. The integration of clinical guidance, AMS principles, policy reform and specialised monitoring tools provides a robust framework for managing evolving treatment landscapes and delivering patient-centred care.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2584
Ward based inhaler technique service reduces use and carbon footprint of short-acting beta-agonist (SABA) inhalers
Introduction: A ward based inhaler technique service achieves significant reductions in rates of asthma and COPD exacerbations and hospital admissions.[1] The impact on SABA inhaler usage has not previously been assessed. Aim: To determine the impact of this service on the use and carbon footprint of SABA inhalers. Methods: Patients admitted to respiratory wards with an exacerbation of asthma or COPD had their inhaler technique assessed and optimised through training or protocol-guided device changes. The number of SABA inhalers issued in primary and secondary care were compared for the 6-months before and after the intervention. Results: Data were available for 86 of 266 patients included in the original study. Use of mixed inhaler devices was more common on admission (usually dry powder inhaler (DPI) maintenance and pMDI reliever inhalers) than using all DPI or all pMDI devices (45, 7, 34 patients respectively). 19 patients using mixed devices agreed to change to use all DPI devices. The median number of SABA inhalers used in the 6 months prior to the intervention was higher for patients using mixed devices (5.5) than those prescribed all pMDI devices (4.0) or all DPI devices (2.4). Fewer SABA inhalers were issued after the intervention (400 vs. 376 over 6 months), and the carbon footprint of SABAs issued reduced significantly (10,060 vs. 7,685 kg CO2e). Conclusions: Inhaler technique optimisation reduces the use of SABA inhalers. The carbon footprint reduced as more DPI SABAs were prescribed. Patients using mixed inhaler devices used more SABA inhalers and should be targeted to ensure consistent prescribing.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2584
Ward based inhaler technique service reduces use and carbon footprint of short-acting beta-agonist (SABA) inhalers
Introduction: A ward based inhaler technique service achieves significant reductions in rates of asthma and COPD exacerbations and hospital admissions.[1] The impact on SABA inhaler usage has not previously been assessed. Aim: To determine the impact of this service on the use and carbon footprint of SABA inhalers. Methods: Patients admitted to respiratory wards with an exacerbation of asthma or COPD had their inhaler technique assessed and optimised through training or protocol-guided device changes. The number of SABA inhalers issued in primary and secondary care were compared for the 6-months before and after the intervention. Results: Data were available for 86 of 266 patients included in the original study. Use of mixed inhaler devices was more common on admission (usually dry powder inhaler (DPI) maintenance and pMDI reliever inhalers) than using all DPI or all pMDI devices (45, 7, 34 patients respectively). 19 patients using mixed devices agreed to change to use all DPI devices. The median number of SABA inhalers used in the 6 months prior to the intervention was higher for patients using mixed devices (5.5) than those prescribed all pMDI devices (4.0) or all DPI devices (2.4). Fewer SABA inhalers were issued after the intervention (400 vs. 376 over 6 months), and the carbon footprint of SABAs issued reduced significantly (10,060 vs. 7,685 kg CO2e). Conclusions: Inhaler technique optimisation reduces the use of SABA inhalers. The carbon footprint reduced as more DPI SABAs were prescribed. Patients using mixed inhaler devices used more SABA inhalers and should be targeted to ensure consistent prescribing.
- Open Access
Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings
Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from opportunistic lung infections by mycobacteria other than Mycobacterium tuberculosis or Mycobacterium leprae species. Similar to many other countries, the incidence of NTM-PD in the United Kingdom (UK) is on the rise for reasons that are yet to be determined. Despite guidelines established by the American Thoracic Society (ATS), the Infectious Diseases Society of America, and the British Thoracic Society, NTM-PD diagnosis and management remain a significant clinical challenge. In this review article, we comprehensively discuss key challenges in NTM-PD diagnosis and management, focusing on the UK healthcare setting. We also propose countermeasures to overcome these challenges and improve the detection and treatment of patients with NTM-PD.
Open AccessSupporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings
Nontuberculous mycobacterial pulmonary disease (NTM-PD) results from opportunistic lung infections by mycobacteria other than Mycobacterium tuberculosis or Mycobacterium leprae species. Similar to many other countries, the incidence of NTM-PD in the United Kingdom (UK) is on the rise for reasons that are yet to be determined. Despite guidelines established by the American Thoracic Society (ATS), the Infectious Diseases Society of America, and the British Thoracic Society, NTM-PD diagnosis and management remain a significant clinical challenge. In this review article, we comprehensively discuss key challenges in NTM-PD diagnosis and management, focusing on the UK healthcare setting. We also propose countermeasures to overcome these challenges and improve the detection and treatment of patients with NTM-PD.
- Open Access
- 25 July 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (745) , 374-376
Asthma: effect of excess short-acting β 2 -agonist (SABA) inhaler prescriptions on healthcare resource utilisation
Asthma management is changing, and the preferred option (track 1) recommended by the Global Initiative for Asthma (GINA) is that all people with asthma should be prescribed an inhaled corticosteroid either as needed in mild asthma or regularly for those with more severe asthma.1 Short acting β2-agonist bronchodilators (SABAs) certainly have an essential role in the management of acute asthma attacks, but their regular use in the chronic management of asthma has recently been highlighted as having potentially dangerous adverse clinical effects, especially when used without inhaled corticosteroids.1,2 The association between excess prescriptions of SABAs and increased asthma attacks, healthcare utilisation, and deaths has been known for decades,3,4 and illustrated so clearly in the SABINA studies5,6 and the UK National Review of Asthma Deaths (NRAD).7 Furthermore, it is 30 years since Suissa et al3,4 demonstrated the association between asthma death and one or more SABA inhaler prescriptions a month with a concomitant reduction in mortality when inhaled corticosteroids (ICS) were used.
- 25 July 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (745) , 374-376
Open AccessAsthma: effect of excess short-acting β 2 -agonist (SABA) inhaler prescriptions on healthcare resource utilisation
Asthma management is changing, and the preferred option (track 1) recommended by the Global Initiative for Asthma (GINA) is that all people with asthma should be prescribed an inhaled corticosteroid either as needed in mild asthma or regularly for those with more severe asthma.1 Short acting β2-agonist bronchodilators (SABAs) certainly have an essential role in the management of acute asthma attacks, but their regular use in the chronic management of asthma has recently been highlighted as having potentially dangerous adverse clinical effects, especially when used without inhaled corticosteroids.1,2 The association between excess prescriptions of SABAs and increased asthma attacks, healthcare utilisation, and deaths has been known for decades,3,4 and illustrated so clearly in the SABINA studies5,6 and the UK National Review of Asthma Deaths (NRAD).7 Furthermore, it is 30 years since Suissa et al3,4 demonstrated the association between asthma death and one or more SABA inhaler prescriptions a month with a concomitant reduction in mortality when inhaled corticosteroids (ICS) were used.
- Open Access
- 25 January 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (739) , 86-89
A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy
Resistance to changing clinical practice in response to scientific evidence is common. Complacency with asthma, and the entrenched overprescribing and overreliance on short-acting β2-agonist bronchodilators (SABAs) in asthma, persists in many parts of the world, including in the UK.1–4 Despite the known morbidity and mortality risks associated with regular and/or excessive use of SABAs, most countries have failed to implement the alternative evidence-based, anti-inflammatory reliever treatment (AIR), as recommended by the Global Initiative for Asthma (GINA) as a better and simpler way to manage asthma (Figure 1).5 This commentary, using the UK as an exemplar, aims to galvanise these countries to adopt an evidence-based and more effective approach to the management of asthma to reduce the risk of severe attacks.
- 25 January 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 74 (739) , 86-89
Open AccessA simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy
Resistance to changing clinical practice in response to scientific evidence is common. Complacency with asthma, and the entrenched overprescribing and overreliance on short-acting β2-agonist bronchodilators (SABAs) in asthma, persists in many parts of the world, including in the UK.1–4 Despite the known morbidity and mortality risks associated with regular and/or excessive use of SABAs, most countries have failed to implement the alternative evidence-based, anti-inflammatory reliever treatment (AIR), as recommended by the Global Initiative for Asthma (GINA) as a better and simpler way to manage asthma (Figure 1).5 This commentary, using the UK as an exemplar, aims to galvanise these countries to adopt an evidence-based and more effective approach to the management of asthma to reduce the risk of severe attacks.
- Open Access
- 10 January 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (2) , 109-114
Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care
The selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters. Factors influencing inhaler choice include measures such as flow rate or pressure drop as well as inhaler technique and patient preference, both of which can lead to improved adherence and outcomes. For optimal disease outcomes, device selection should be individualised, inhaler technique optimised and patient preference considered. By addressing the common clinically relevant questions, this paper aims to demystify how DPI resistance should guide the selection of the right device for the right patient.
- 10 January 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (2) , 109-114
Open AccessDemystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care
The selection of an inhaler device is a key component of respiratory disease management. However, there is a lack of clarity surrounding inhaler resistance and how it impacts inhaler selection. The most common inhaler types are dry powder inhalers (DPIs) that have internal resistance and pressurised metered dose inhalers (pMDIs) that use propellants to deliver the drug dose to the airways. Inhaler resistance varies across the DPIs available on the market, depending largely on the design geometry of the device but also partially on formulation parameters. Factors influencing inhaler choice include measures such as flow rate or pressure drop as well as inhaler technique and patient preference, both of which can lead to improved adherence and outcomes. For optimal disease outcomes, device selection should be individualised, inhaler technique optimised and patient preference considered. By addressing the common clinically relevant questions, this paper aims to demystify how DPI resistance should guide the selection of the right device for the right patient.
- Open Access
- 9 February 2023
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 7 (3)
Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study
Background: Poor asthma control is associated with high short-acting β2-agonist (SABA) use.Aim: To assess asthma-related healthcare resource utilisation (HCRU) and medication costs associated with high versus low SABA prescriptions in the UK.Design & setting: Analysis of SABINA I (SABA use IN Asthma I), a retrospective longitudinal study using UK electronic health records (Clinical Practice Research Datalink GOLD 2008−2019 and Hospital Episode Statistics database).Method: Eligible patients were ≥12 years old with SABA prescriptions in the past year. SABA prescriptions (number of canisters per year) were defined as high (≥3) or low (1–2). Association of SABA prescriptions with HCRU was assessed by negative binominal model adjusted for covariates. The UK unit costs from the NHS were applied to estimate total healthcare costs (2020). Medication costs were based on the annual average number of canisters per year per patient.Results: Overall, 186 061 patients with SABA prescriptions were included, of whom 51% were prescribed high SABA. Total annual average costs (HCRU and medication) were 52% higher in the high SABA group versus the low SABA group (£2 256 091 per 1000 patients/year versus £1 480 640 per 1000 patients/year). Medication costs accounted for the majority of asthma-related costs. Across both groups, most HCRU costs were for non–exacerbation-related primary care or hospital outpatient visits. The annual average HCRU cost difference for high SABA versus low SABA was the greatest for hospitalisations (+230%; £15 521 per 1000 patients/year versus £4697 per 1000 patients/year) and exacerbation-related primary care visits (+162%; £18 770 per 1000 patients/year versus £7160 per 1000 patients/year). Asthma-related HCRU extrapolated to the broader UK asthma population was £108.5 million per year higher with high SABA versus low SABA.Conclusion: High SABA versus low SABA prescriptions are associated with higher asthma-related HCRU costs.
- 9 February 2023
- Published by Royal College of General Practitioners in BJGP Open
- Vol. 7 (3)
Open AccessHealthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study
Background: Poor asthma control is associated with high short-acting β2-agonist (SABA) use.Aim: To assess asthma-related healthcare resource utilisation (HCRU) and medication costs associated with high versus low SABA prescriptions in the UK.Design & setting: Analysis of SABINA I (SABA use IN Asthma I), a retrospective longitudinal study using UK electronic health records (Clinical Practice Research Datalink GOLD 2008−2019 and Hospital Episode Statistics database).Method: Eligible patients were ≥12 years old with SABA prescriptions in the past year. SABA prescriptions (number of canisters per year) were defined as high (≥3) or low (1–2). Association of SABA prescriptions with HCRU was assessed by negative binominal model adjusted for covariates. The UK unit costs from the NHS were applied to estimate total healthcare costs (2020). Medication costs were based on the annual average number of canisters per year per patient.Results: Overall, 186 061 patients with SABA prescriptions were included, of whom 51% were prescribed high SABA. Total annual average costs (HCRU and medication) were 52% higher in the high SABA group versus the low SABA group (£2 256 091 per 1000 patients/year versus £1 480 640 per 1000 patients/year). Medication costs accounted for the majority of asthma-related costs. Across both groups, most HCRU costs were for non–exacerbation-related primary care or hospital outpatient visits. The annual average HCRU cost difference for high SABA versus low SABA was the greatest for hospitalisations (+230%; £15 521 per 1000 patients/year versus £4697 per 1000 patients/year) and exacerbation-related primary care visits (+162%; £18 770 per 1000 patients/year versus £7160 per 1000 patients/year). Asthma-related HCRU extrapolated to the broader UK asthma population was £108.5 million per year higher with high SABA versus low SABA.Conclusion: High SABA versus low SABA prescriptions are associated with higher asthma-related HCRU costs.
- Open Access
Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK
Objectives The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations. Design Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy. Setting Primary care practices in the UK (1-year time horizon). Participants Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531). Interventions Inhaler maintenance therapy. Outcome measures Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways. Results Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. Total cost savings of up to 8% annually could be achieved by treatment of patients according to either of these recommendations. Cost savings arose from a reduction in the rates of pneumonia, with an associated decrease in costs associated with antibiotic use and hospitalisation. Savings were achieved overall despite a small increase in the rate of exacerbations due to the redistribution of certain patients currently undergoing triple inhaled therapy to therapies not containing inhaled corticosteroids. Conclusion Redistribution of patients with COPD from current clinical practice to treatment according to published recommendations would provide substantial cost savings over the first year.
Open AccessCost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK
Objectives The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations. Design Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy. Setting Primary care practices in the UK (1-year time horizon). Participants Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531). Interventions Inhaler maintenance therapy. Outcome measures Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways. Results Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. Total cost savings of up to 8% annually could be achieved by treatment of patients according to either of these recommendations. Cost savings arose from a reduction in the rates of pneumonia, with an associated decrease in costs associated with antibiotic use and hospitalisation. Savings were achieved overall despite a small increase in the rate of exacerbations due to the redistribution of certain patients currently undergoing triple inhaled therapy to therapies not containing inhaled corticosteroids. Conclusion Redistribution of patients with COPD from current clinical practice to treatment according to published recommendations would provide substantial cost savings over the first year.